Arcadia Biosciences, Inc. (RKDA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 600K 1.2M 1.8M Q3 '24: 1.5M Q4 '24: 1.2M Q1 '25: 1.2M Q2 '25: 1.5M Q3 '25: 1.3M Q4 '25: 901K Q1 '26: 1.1M Q2 '26: 1.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 250K 500K 750K Q3 '24: 505K Q4 '24: 389K Q1 '25: 518K Q2 '25: 631K Q3 '25: 418K Q4 '25: 192K Q1 '26: 400K Q2 '26: 631K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q3 '24: -1.8M Q4 '24: -2.3M Q1 '25: 530K Q2 '25: -501K Q3 '25: -1.2M Q4 '25: -1.4M Q1 '26: -779K Q2 '26: -496K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '24: -1.6M Q4 '24: -4.1M Q1 '25: 2.6M Q2 '25: -4.5M Q3 '25: 856K Q4 '25: -1.3M Q1 '26: -4.4M Q2 '26: -6.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 400K 800K 1.2M Q3 '24: 1M Q4 '24: 827K Q1 '25: 682K Q2 '25: 824K Q3 '25: 884K Q4 '25: 709K Q1 '26: 700K Q2 '26: 812K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q3 '24: -1.8M Q4 '24: -2.2M Q1 '25: -1.6M Q2 '25: -2M Q3 '25: -257K Q4 '25: -861K Q1 '26: -1.1M Q2 '26: -319K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '24: -3.2M Q2 '24: -2.5M Q3 '24: -1.8M Q4 '24: -2.2M Q1 '25: -1.6M Q2 '25: -2M Q3 '25: -257K Q4 '25: -861K Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 1.5M 3M 4.5M Q1 '24: 1.4M Q2 '24: 1.4M Q3 '24: 1.4M Q1 '25: 1.4M Q2 '25: 1.4M Q3 '25: 1.4M Q1 '26: 2.1M Q2 '26: 3M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '24: -4.16 Q4 '24: -5.17 Q1 '25: -1.49 Q2 '25: -5.53 Q3 '25: -3.73 Q4 '25: -1.71 Q1 '26: -5.72 Q2 '26: -4.55 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.